Evidence map›Paper›PMID 29416792›Full record

ArticleOncotarget2018

CancerDiscover: an integrative pipeline for cancer biomarker and cancer class prediction from high-throughput sequencing data.

Akram Mohammed, Greyson Biegert, Jiri Adamec, Tomáš Helikar

Abstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Akram Mohammed *Department of Biochemistry, University of Nebraska-Lincoln, Lincoln, Nebraska, United States of America.
Greyson Biegert *Department of Biochemistry, University of Nebraska-Lincoln, Lincoln, Nebraska, United States of America.
Jiri AdamecDepartment of Biochemistry, University of Nebraska-Lincoln, Lincoln, Nebraska, United States of America.
Tomáš HelikarDepartment of Biochemistry, University of Nebraska-Lincoln, Lincoln, Nebraska, United States of America.

Funding

Software for collaborative construction, simulation, and analysis of mechanistic computational models of biological systemsR35GM119770 · NIGMS · UNIVERSITY OF NEBRASKA LINCOLN · PI Tomas Helikar · 2016 to 2026
$4.4M
NIGMS NIH HHS R35 GM119770
6 · The paper itself

Abstract

Accurate identification of cancer biomarkers and classification of cancer type and subtype from High Throughput Sequencing (HTS) data is a challenging problem because it requires manual processing of raw HTS data from various sequencing platforms, quality control, and normalization, which are both tedious and time-consuming. Machine learning techniques for cancer class prediction and biomarker discovery can hasten cancer detection and significantly improve prognosis. To date, great research efforts have been taken for cancer biomarker identification and cancer class prediction. However, currently available tools and pipelines lack flexibility in data preprocessing, running multiple feature selection methods and learning algorithms, therefore, developing a freely available and easy-to-use program is strongly demanded by researchers. Here, we propose CancerDiscover, an integrative open-source software pipeline that allows users to automatically and efficiently process large high-throughput raw datasets, normalize, and selects best performing features from multiple feature selection algorithms. Additionally, the integrative pipeline lets users apply different feature thresholds to identify cancer biomarkers and build various training models to distinguish different types and subtypes of cancer. The open-source software is available at https://github.com/HelikarLab/CancerDiscover and is free for use under the GPL3 license.

Indexed as

cancer biomarkercancer classificationgene expressionmachine learningopen-source

Identifiers

PMID29416792
PMCPMC5788660

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.